SARMsHigh risk

RAD-150 (TLB-150)

Also known as: RAD-150, TLB-150, TLB150, Testolone benzoate, RAD150

Sold as an esterified RAD-140 with a longer duration. The chemistry is plausible, the evidence is nonexistent, and even the identity of what is sold is unverified.

Substance family

SARMs

Non-steroidal compounds binding the same androgen receptor as testosterone, but favouring muscle and bone over prostate and hair. The selectivity is real; the suppression of the body's own production is not avoided by it. None is approved anywhere.

Effects on

Muscle & strength

Which outcomes this substance acts on — descriptive, not a recommendation.

Strain profile

Where this substance is most likely to hit — a rough orientation, individually dependent on dose, duration and predisposition.

Liver

medium

Kidneys

minimal

Blood lipids

high

Hematocrit

minimal

Blood pressure

low

Hormonal axis

high

This substance causes

Own production suppressed HDL drops, LDL rises Liver strain Acne, oily skin

Dosing & protocols by goal

Rough orientation ranges as reported in harm-reduction literature — not an individual treatment plan. Doses are individual and open-ended; frequency depends on the ester or half-life.

Research data

Medical

Dose

Does not exist

Frequency

—

Cycle length

—

Unlike the other compounds in this category, RAD-150 has no research record at all — not even preclinical. It appeared on the grey market rather than emerging from a development programme.

Grey market practice

Not a recommendation

Dose

10–20 mg / day reported

Frequency

1× daily

Cycle length

6–8 weeks reported

Figures copied from RAD-140 dosing. Whether they transfer to an ester with different release kinetics is unknown, and would depend on the ester actually being present.

Supraphysiological doses carry significant health risks and are not legal without a medical indication. This information serves education and harm reduction, not as a usage recommendation. Accompanying blood work and — where relevant — a post-cycle plan (PCT) are essential. See the disclaimer.

Side effect & countermeasure

Typical problems and what you can do to reduce harm — at a glance. Does not replace medical monitoring.

Problem

The identity of what is sold is unverified

Countermeasure

RAD-150 is described as testolone benzoate — RAD-140 with a benzoate ester attached. That is chemically coherent, and it is also the entire basis for the product. There is no published synthesis, no characterisation, no pharmacokinetic data. Independent analyses of products sold as RAD-150 have found plain RAD-140. Someone buying this may simply be paying more for the compound they could have bought directly.

Problem

Esterification does not work the same way orally

Countermeasure

The ester concept comes from injectable steroids, where the ester slows release from an oil depot in muscle. That mechanism requires a depot. An oral ester is cleaved in the gut and liver, and whether it meaningfully extends duration depends entirely on the specific chemistry — which has not been measured here. The marketing borrows the logic of injectable esters without the mechanism that makes it work.

Problem

It carries RAD-140's risks by design

Countermeasure

If the product is what it claims, it delivers RAD-140. That means the same strong suppression, the same effect on lipids and the elevated liver values that RAD-140 users report — including several published case reports of drug-induced liver injury. Nothing about adding an ester reduces those.

Problem

Severe suppression

Countermeasure

RAD-140 is among the more suppressive SARMs, and an ester intended to extend exposure does not soften that. PCT with enclomiphene or clomiphene, bloodwork before and after.

Overview

RAD-150 is the newest entry in this category and the one with the least behind it. It differs from every other compound on these pages in an important way: it did not come from a research programme at all.

Ostarine, LGD-4033, andarine, S-23, ACP-105 and the rest are real compounds with development histories, however incomplete. RAD-150 appeared on the grey market as a product.

What It Is Claimed To Be

The description is that RAD-150 — also sold as TLB-150 — is RAD-140 with a benzoate ester attached, producing a longer duration of action and more stable blood levels.

The chemistry of that idea is coherent. Esterification is a real and well-understood technique, and it is exactly how testosterone enanthate and trenbolone acetate work.

What is missing is everything else. There is no published synthesis, no characterisation data, no pharmacokinetic study, no measurement of half-life confirming the longer duration. There is a product description.

The Problem With Borrowing Ester Logic

The ester concept comes from injectables. An oil-based steroid sits in a muscle depot, enzymes cleave the ester off gradually, and the active compound releases slowly. The depot is essential to the mechanism.

An oral compound has no depot. It is absorbed through the gut and passes through the liver, where esters are cleaved rapidly. Whether an oral ester meaningfully extends duration depends on specific properties that would have to be measured — and here they have not been.

So the claim uses the vocabulary of injectable esters in a context where the underlying mechanism does not automatically apply.

The Practical Question

Independent analyses of products sold as RAD-150 have found ordinary RAD-140 inside.

That leaves two possibilities, neither good. Either the product is RAD-140 relabelled, in which case the buyer is paying a premium for nothing. Or it genuinely is the ester, in which case it delivers RAD-140 anyway once cleaved — with the same suppression, the same lipid damage, and the same liver risk that has produced published case reports of liver injury with RAD-140.

In both cases, what arrives is RAD-140. The ester adds cost and uncertainty rather than a benefit anyone has demonstrated.

Side Effects & Risks

Everything associated with RAD-140: strong suppression, severe HDL suppression, elevated liver values
Documented case reports of drug-induced liver injury with the parent compound
Complete absence of characterisation data for the ester itself
High likelihood that the product is not what the label says
No manufacturing oversight

Blood Work & Monitoring

Liver values (ALT, AST, GGT, bilirubin) — RAD-140 has case reports of liver injury; this is the priority
Total and free testosterone, LH, FSH — before, during and after
Lipid profile (LDL, HDL, ApoB)
Estradiol (sensitive assay)

Legal status by region

Regulation differs considerably between jurisdictions and changes over time. This is a rough orientation, not legal advice — check the rules that apply where you are.

Region	Regulatory status
United States	Not approved; FDA warning applies to the SARM category
EU / UK	No marketing authorisation
Most other jurisdictions	Unregulated grey area
Competitive sport	Prohibited at all timesAs a claimed RAD-140 derivative it falls under WADA S1.2, and it would metabolise to a detectable parent compound.

All content on this page is for information and harm-reduction purposes only. It is not medical advice, not a recommendation to purchase or use, and does not replace consulting a doctor. Legal status and enforcement vary by country and change; verifying the current rules in your own jurisdiction is your responsibility. For adults 18+ only. See the full disclaimer.